The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: A systematic review

Journal of Dermatological Treatment

Volumn 24, Issue 5, 2013, Pages 392-404

  Van Rappard, Dominique C ^a   Limpens, Jacqueline ^b   Mekkes, Jan R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Acne inversa; Adalimumab; Biological; Etanercept; Hidradenitis suppurativa; Infliximab; TNF inhibitor

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MYALGIA; OFF LABEL DRUG USE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SUPPURATIVE HIDRADENITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNOGLOBULIN G; OFF-LABEL USE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883579124     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.674193     Document Type: Review

References (77)

1. Jemec GB. Hidradenitis suppurativa. J Cutan Med Surg. 2003;7:47-56
2. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: Surgical approach. In Roenighk RK, Roenigk HH, editors. Dermatologic surgery. New York: Marcel Dekker, 1989. pp 729-739
3. Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: A qualitative study. Acta Derm Venereol. 2011; 91:328-332
4. Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23:985-998
5. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2:9-16
6. Ather S, Chan DS, Leaper DJ, Harding KG. Surgical treatment of hidradenitis suppurativa: Case series and review of the literature. Int Wound J. 2006;3:159-169
7. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: Response to treatment with infliximab. Inflamm Bowel Dis. 2001;7:323-326
8. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol. 2009;89:595-600
9. Higgins JP, Green S. Assessing risk of bias in included studies. section 8.5 cochrane handbook for systematic reviews of interventions, version 5.1.0 web site. http://www.cochranehandbook. org/.
10. Robinson JK, Dellavalle RP, Bigby M, Callen JP. Systematic reviews: Grading recommendations and evidence quality. Arch Dermatol. 2008;144:97-99
11. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol. 2002;97: 2155-2156
12. Roussomoustakaki M, Dimoulios P, Chatzicostas C, Kritikos HD, Romanos J, Panayiotides JG, et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: Response to anti-TNF therapy. J Gastroenterol. 2003;38:1000-1004
13. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2003;49: S275-S276
14. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149:1046-1049
15. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch dermatol. 2003;139:1540-1542
16. Mekkes JR, Hommes DW. Treatment of suppurative hidradenitis with surgical deroofing and infliximab. Ned Tijdschr Dermatol Venereol. 2004;14:196-197
17. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat. 2005;16:58-61
18. Ravat F, O'Reilly D, Handfield-Jones S. Recalcitrant hidradenitis suppurativa treated with adalimumab. J Am Acad Dermatol. 2005;52:P58
19. Suys E, D'Heygere F. Infliximab for acne inversa (alias hidradenitis supporativa)? Ned Tijdschr Dermatol Venereol. 2005;15:406-407
20. Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol. 2006;155: 1105-1107
21. Maalouf E, FayeO, Poli F, Cosnes A, Revuz J. Fatal epidermoid carcinoma in hidradenitis suppurativa following treatment with infliximab. Ann Dermatol Venereol. 2006;133:473-474
22. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624-628
23. Usmani N, Clayton TH, Everett S, Goodfield MD. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32:204-205
24. Pedraz J, Dauden E, Perez-Gala S, Goiriz-Valdes R, Fernandez-Penas P, Garcia-Diez A. Hidradenitis suppurativa. response to treatment with infliximab. Actas Dermosifiliogr. 2007;98:325-331
25. Fernandez-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology. 2007; 215:41-44
26. Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativäa report of three treated cases. Int J Dermatol. 2007;46:1287-1291
27. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008; 158:370-374
28. Antonucci A, Negosanti M, Negosanti L, Iozzo I, Varotti C. Acne inversa treated with infliximab: Different outcomes in 2 patients. Acta Derm Venereol. 2008;88:274- 275
29. Pedraz J, Penas PF, Garcia-Diez A. Pachyonychia congenita and hidradenitis suppurativa: No response to infliximab therapy. J Eur Acad Dermatol Venereol. 2008;22: 1500-1501
30. Elkjaer M, Dinesen L, Benazzato L, Rodriguez J, Logager V, Munkholm P. Efficacy of Infliximab treatment in patients with severe Fistulizing Hidradenitis Suppurativa. J Crohns Colitis. 2008;2:241-245
31. Brunasso AM, Delfino C, Massone C. Hidradenitis suppurativa: Are tumour necrosis factor-alpha blockers the ultimate alternative? Br J Dermatol. 2008;159:761-763
32. Kwan CK, Chong LY. A Chinese man with chronic recalcitrant hidradenitis suppurativa successfully treated with infliximab. Hong Kong J Dermatol Venereol. 2008;16: 206-210
33. Montes-Romero JA, Callejas-Rubio JL, Sanchez-Cano D, Gonzalez-Martinez FJ, Navas-Parejo A, Ortego-Centeno N. Amyloidosis secondary to hidradenitis suppurativa. exceptional response to infliximab. Eur J Intern Med. 2008;19: E32-e33
34. Benitez-Macias JF, Garcia-Gil D, Brun-Romero FM. Fatal pneumococcal sepsis in a patient with hidradenitis suppurativa treated with infliximab. Med Clin (Barc). 2008;131:799
35. Obadia DL, Daxbacher EL, Jeunon T, Gripp AC. Hidradenitis suppurativa treated with infliximab. An Bras Dermatol. 2009;84:695-697
36. Goertz RS, Konturek PC, Naegel A, Janka R, Amann K, Maennlein G, et al. Experiences with a long-term treatment of a massive gluteal acne inversa with infliximab in Crohn's disease. Med Sci Monit. 2009;15:CS14-CS18
37. Poulin Y. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. J Cutan Med Surg. 2009;13:221-225
38. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol. 2009;66: 490-497
39. Yamauchi PS, Mau N. Hidradenitis suppurativa managed with adalimumab. J Drugs Dermatol. 2009;8:181-183
40. Deschamps ME, Payet S, Tournadre A, Soubrier M, Souteyrand P, D'Incan M. Efficacy of infliximab in the treatment of follicular occlusion triad. Ann Dermatol Venereol. 2010;137:546-550
41. Garcia-Rabasco AE, Esteve-Martinez A, Zaragoza-Ninet V, Sanchez-Carazo JL, Alegre-de-Miquel V. Pyoderma gangrenosum associated with hidradenitis suppurativa: A case report and review of the literature. Actas Dermosifiliogr. 2010;101: 717-721
42. Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: A case series and literature review. Arch Dermatol. 2010;146:1265-1270
43. Yazdanyar S, Miller IM, Jemec GBE. Hidradenitis suppurativa and Crohn's disease: Two cases that support an association. Acta Dermatovenerol Alp Pannonica Adriat. 2010;19: 23-25
44. Lasocki A, Sinclair R, Foley P, Saunders H. Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol. 2010;51:186-190
45. Alecsandru D, Padilla B, Izquierdo JA, Fernandez-Cruz E, Sanchez-Ramon S. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol. 2010;146:1343-1345
46. Torres T, Selores M. Treatment of hidradenitis suppurativa with infliximab. An Bras Dermatol. 2010;85:576
47. Fernandez OP, Alonso RB, Villa I, Lopez MG, Llaca HF, Del CG-V,et al. Adalimumab therapy in 18 patients with severe hidradenitis suppurativa. Arthritis Rheum. 2010;62:1650
48. Moreira A, Baptista A, Leite I, Guedes R. Successful long-term infliximab therapy in severe recalcitrant hidradenitis suppurativa. J Am Acad Dermatol. 2010;62 (3 Suppl 1):AB32
49. Delage M, Samimi M, Atlan M, Machet L, Lorette G, Maruani A. Efficacy of infliximab for hidradenitis suppurativa: Assessment of clinical and biological inflammatory markers. Acta Derm Venereol. 2011;91:169-171
50. vanRappardDC,MooijJE,BaetenDLP,Mekkes JR.New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab. Br J Dermatol. 2011;165:194-198
51. Husein-ElAhmed H, O'Valle F, Aneiros-Fernandez J, Jimenez JPM, Arias-Santiago S. Case of extensive inguinal hidradenitis suppurativa. J AmAcad Dermatol. 2011;64(2 Suppl 1):AB38
52. Jurgensmeyer JC, Fleischer A. Clinical improvement of refractory hidradenitis suppurativa with etanercept. J Am Acad Dermatol. 2004;50:P15
53. Cusack C, Buckley C. Etanercept: Effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154: 726-729
54. Henderson RLJ. Case reports: Treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor- Fc fusion protein etanercept. J Drugs Dermatol. 2006;5: 1010-1011
55. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158: 567-572
56. Zangrilli A, Esposito M, Mio G,Mazzotta A, Chimenti S. Longterm efficacy of etanercept in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2008;22:1260-1262
57. Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60:565-573
58. Sotiriou E, Apalla Z, Ioannidos D. Etanercept for the treatment of hidradenitis suppurativa. Acta Derm Venereol. 2009; 89:82-83
59. Blanco R, Martinez-Taboada VM, Villa I, Gonzalez- Vela MC, Fernandez-Llaca H, Agudo M, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch dermatol. 2009;145:580-584
60. Moran B, Rogers SCF, Kirby B. Resistant hidradenitis suppurativa treated with adalimumab. Br J Dermatol. 2009;161:57
61. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradentis supprativa with adalimumab. J Am Acad Dermatol. 2006;55:163-164
62. Moul DK, Korman NJ. Severe hidradenitis suppurativa treated with adalimumab. Arch dermatol. 2006;142: 1110-1112
63. Sotiriou E, Apalla Z, Vakirlis E, Ioannides D. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol. 2009;19:180-181
64. Harde V, Mrowietz U. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab. J Dtsch Dermatol Ges. 2009;7:139-141. [Epub ahead of print]
65. Koilakou S, Karapiperis D, Tzathas C. A case of hidradenitis suppurativa refractory to anti-TNFalpha therapy in a patient with Crohn's disease. Am J Gastroenterol. 2010;105: 231-232
66. Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49:950-955
67. Alzaga Fernandez AG, Demirci H, Darnley-Fisch DA, Steen DW. Interstitial keratitis secondary to severe hidradenitis suppurativa: A case report and literature review. Cornea. 2010;29:1189-1191
68. Arenbergerova M, Gkalpakiotis S, Arenberger P. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. Int J Dermatol. 2010;49:1445-1449
69. van Rappard DC, Leenarts MF, Meijerink-van 't OL, Mekkes Jr. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat. 2011
70. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205-217
71. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501-504
72. Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double blind Placebo Controlled randomised Trial of Adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:391-398
73. Kimball A, Jemec G, Okun M, Gu Y. Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: Results from the placebo-controlled portion of a phase II, randomized, double- blind study. J Am Acad Dermatol. 2011;64(2 Suppl 1): AB155
74. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: A study of 61 cases. J Am Acad Dermatol. 2007;56:621-623
75. Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161: 831-839
76. Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2011. [Epub ahead of print]
77. Strober BE, Kim C, Siu K. Efalizumab for the treatment of refractory hidradenitis suppurativa. J Am Acad Dermatol. 2007;57:1090-1091